icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Renewal of inclusion
Clinical Benefit
Substantial
The actual benefit of DOTAREM remains substantial.
Clinical Added Value
minor
DOTAREM offers a minor improvement in actual benefit (level IV) in terms of safety over gadolinium-based contrast media presenting a high (OMNISCAN, MAGNEVIST) or moderate (MULTIHANCE) risk of nephrogenic systemic fibrosis according to the European Medicines Agency classification.
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
efUtqt8ZGvphuUN9